A Study to Improve Skeletal Muscle in Veterans With HIV

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-15

Study Completion Date

2029-06-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Department of Veterans Affairs is the largest single provider of medical care to people with HIV in the United States. The condition of excess lipid within and around muscle, termed myosteatosis, predisposes Veterans to physical function decline, frailty, disability, and cardiometabolic diseases such as diabetes and cardiovascular disease. In the investigators current Merit supported cohort, the investigators found that 36% of Veterans with treated HIV and obesity have "myosteatotic type obesity". Based on the investigators findings, the investigators have designed a multipronged integrated intervention that combines: 1) dietary replacement of saturated with unsaturated fats; 2) administration of L-carnitine and omega-3 fatty acid supplementation; and 3) targeted resistance exercise training.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Strength Training and Endurance Exercise for LIFE

NCT02101060

HIV

COMPLETED NA

The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease

NCT06113003

HIV Non-Alcoholic Fatty Liver Disease Metabolic-Associated Steatotic Liver Disease

RECRUITING EARLY_PHASE1

A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients

NCT00000890

HIV Infections

COMPLETED

The Use of Nutropin Depot in HIV-infected Adult Males

NCT00286676

HIV Infection

WITHDRAWN PHASE2/PHASE3

Functional Interval Training for Veterans Exercising Through Telehealth.

NCT04103593

HIV Infection

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Department of Veterans Affairs is the largest single provider of medical care to people with HIV in the United States. With the advances achieved in antiretroviral therapy (ART), Veterans with HIV now survive decades. However, this success is tempered by the rising burden of obesity now affecting 78% of Veterans. Defects in adipose tissue lipid storage and regulation are hallmarks of both treated HIV and obesity, which leads to a high degree of ectopic fat infiltrating organs and tissues such as skeletal muscle. The condition of excess lipid within and around muscle, termed myosteatosis, predisposes Veterans to physical function decline, frailty, disability, and cardiometabolic diseases such as diabetes and cardiovascular disease. In the investigators current Merit supported cohort, the investigators found that 36% of Veterans with treated HIV and obesity have "myosteatotic type obesity". Further, the investigators found that high ectopic fat accumulation in muscle (quantified by CT imaging of skeletal muscle density) is associated with reduced mitochondrial oxidative capacity, greater inflammation, and impaired muscle glucose tolerance and insulin sensitivity. Hence the quality of muscle is just as important as the quantity of muscle. However, this important phenomenon has received little attention, especially in Veterans with HIV. Indeed, the need to target mobilizing and metabolizing skeletal muscle ectopic fat while preserving/increasing the total amount of skeletal muscle is most often overlooked and represents a major research gap and unmet clinical need. From the investigators current Merit Award funded study, the investigators have an established collaboration of experienced VA researchers with expertise in HIV and immunology, human nutrition and metabolism, endocrinology, radiology and imaging science, and muscle physiology. Based on the investigators findings, the investigators have designed a multipronged integrated intervention that combines: 1) dietary replacement of saturated with unsaturated fats; 2) administration of L-carnitine and omega-3 fatty acid supplementation; and 3) targeted resistance exercise training. This evidence-based intervention is designed to: a) increase lipid flux by facilitating the transfer of long-chain fatty acids into muscle mitochondria for -oxidation; b) decrease muscle proteolysis; and c) lessen insulin resistance and inflammation. Using a mixed 2x4 factorial design trial design in a cohort of 60 Veterans who have HIV and obesity, this study will determine the main and interaction effects of the multi-pronged intervention on: skeletal muscle density, mitochondrial oxidative capacity, and fatty acid oxidation (Aim 1); glucose tolerance, insulin sensitivity, and inflammation (Aim 2); and cardiopulmonary exercise tolerance and physical function (Aim 3). Obesity in Veterans with treated HIV is a heterogeneous condition. The investigators current Merit research shows myosteatotic obesity is a distinct condition from visceral or steatotic or sarcopenic obesity, affected by different clinical factors. The investigators findings to date provide the foundation for a novel evidence-based intervention that has the potential for significant clinical impact on Veterans, including and beyond those with HIV. This proposal meets VA-ORD priorities to improve health behaviors, focus on underserved Veterans, and provide precision care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Randomization to one of 4 groups: Diet control group, Diet + w-3 supplement, Diet + L-carnitine supplement, Diet + w-3 + l-carnitine, followed by addition of resistance exercise training in each group, total intervention period is 4 weeks

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

PI blinded to randomization group

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Diet

Diet high in unsaturated fat

Group Type PLACEBO_COMPARATOR

Control Diet

Intervention Type OTHER

Control Diet high in unsaturated fat

Diet + w-3 fatty acids

Diet high in unsaturated fat plus omega-3 fatty acid supplement

Group Type EXPERIMENTAL

w-3 fatty acid

Intervention Type DIETARY_SUPPLEMENT

omega-3 fatty acid supplement

Control Diet

Intervention Type OTHER

Control Diet high in unsaturated fat

Diet + L-Carnitine

Diet high in unsaturated fat plus L-carnitine supplement

Group Type EXPERIMENTAL

L-carnitine

Intervention Type DIETARY_SUPPLEMENT

L-carnitine supplement

Control Diet

Intervention Type OTHER

Control Diet high in unsaturated fat

Diet + w-3 fatty acids + L-carnitine

Diet high in unsaturated fat plus omega-3 fatty acid supplement plus L-carnitine supplement

Group Type EXPERIMENTAL

w-3 fatty acid

Intervention Type DIETARY_SUPPLEMENT

omega-3 fatty acid supplement

L-carnitine

Intervention Type DIETARY_SUPPLEMENT

L-carnitine supplement

Control Diet

Intervention Type OTHER

Control Diet high in unsaturated fat

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

w-3 fatty acid

omega-3 fatty acid supplement

Intervention Type DIETARY_SUPPLEMENT

L-carnitine

L-carnitine supplement

Intervention Type DIETARY_SUPPLEMENT

Control Diet

Control Diet high in unsaturated fat

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Veteran
* HIV+
* antiretroviral therapy = integrase strand transfer inhibitor for at least 3 months
* HIV-1 RNA \<50 copies/ml
* age = 20 yrs
* BMI 28-50 kg/m2

Exclusion Criteria

* unstable body weight (gain or loss \> 5% over past 3 months)
* diagnosed mitochondrial disorder
* diagnosed type 1 or type 2 diabetes
* use of metformin or other anti-diabetic agents for pre-diabetes
* hemoglobin A1c of \>6.5% at screening visit
* inflammatory conditions or chronic corticosteroid use
* stage 3 or greater kidney disease
* dietary or herbal supplements known to affect body weight, muscle mass, or immune function
* MRI incompatibility
* inability to perform physical function tests due to anatomical limitations
* contradictions to CPET such as exercise-induced ischemia or supplemental oxygen

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No